Researcher
Quentin Lecocq
- Research Expertise:
Expertise: Tumor immunology.
We evaluate the use of single domain antibodies (sdAbs), also known as nanobodies, as targeting moieties for therapeutic and diagnostic applications.
- Keywords:Medicine
- Disciplines:Medical and health sciences, Social sciences
- Users of research expertise:
Expertise: Tumor immunology.
We evaluate the use of single domain antibodies (sdAbs), also known as nanobodies, as targeting moieties for therapeutic and diagnostic applications.
Affiliations
- Laboratory of Molecullar and Cellular Therapy (Research group)
Member
From19 Mar 2021 → Today - Basic (bio-) Medical Sciences (Department)
Member
From1 Jan 2018 → 31 Dec 2021 - Basic (bio-) Medical Sciences (Department)
Member
From1 Oct 2016 → 30 Sep 2021 - Faculty of Medicine and Pharmacy (Faculty)
Member
From18 Aug 2016 → 23 Nov 2021 - Faculty of Medicine and Pharmacy (Faculty)
Member
From31 Aug 2014 → 21 Jun 2016
Projects
1 - 1 of 1
- Nanobody-mediated imaging and blocking of the inhibitory receptor LAG-3From1 Jan 2018 → 31 Dec 2021Funding: FWO fellowships
Publications
1 - 10 of 20
- Phase I Study of [68Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I)(2023)
Authors: Odrade Gondry, Catarina Xavier, Laurens Raes, Johannes Heemskerk, Nick Devoogdt, Hendrik Everaert, K Breckpot, Q Lecocq, Lore Decoster, Christel Fontaine, et al.
Pages: 1378-1384 - Targeted radionuclide therapy with low and high-dose Lutetium-177 labeled single domain antibodies induces distinct immune signatures in a mouse melanoma model(2022)
Authors: T Ertveldt, L De Beck, Kirsten De Ridder, Hanne Locy, Wout De Mey, Cleo Goyvaerts, Q Lecocq, Hannelore Ceuppens, Y De Vlaeminck, R M Awad, et al.
Pages: 1136-1148 - Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma(2022)
Authors: L De Beck, R M Awad, Veronica Basso, Noelia Casares, Kirsten De Ridder, Y De Vlaeminck, Alessandra Gnata, Cleo Goyvaerts, Q Lecocq, Edurne San José-Enériz, et al.
Pages: 1-15 - TNF-alpha-Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy(2022)
Authors: Kirsten De Ridder, Hanne Locy, Elisa Piccioni, Miren Ibarra Zuazo, R M Awad, Stefaan Verhulst, Mathias Van Bulck, Y De Vlaeminck, Q Lecocq, Eva Reijmen, et al.
Pages: 1-15 - Emerging applications of nanobodies in cancer therapy(2022)
Authors: R M Awad, Fien Meeus, Hannelore Ceuppens, T Ertveldt, Heleen Hanssens, Q Lecocq, Lukasz Mateusiak, Katty Zeven, Hana Valenta, Timo W M De Groof, et al.
Pages: 143-199 - Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer(2021)
Authors: Q Lecocq, P Debie, Janik Puttemans, R M Awad, L De Beck, T Ertveldt, Y De Vlaeminck, Cleo Goyvaerts, G Raes, M Keyaerts, et al.
- Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade(2021)
Authors: Q Lecocq, R M Awad, Y De Vlaeminck, Wout De Mey, T Ertveldt, Cleo Goyvaerts, G Raes, Kris Thielemans, M Keyaerts, Nick Devoogdt, et al.
Pages: 1638-1644 - Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade(2021)
Authors: R M Awad, Q Lecocq, Katty Zeven, T Ertveldt, L De Beck, Hannelore Ceuppens, Katrijn Broos, Y De Vlaeminck, Cleo Goyvaerts, Magali Verdonck, et al.
Pages: 172-182 - Developing nanobodies to advance immune checkpoint therapy that targets lymphocyteactivation gene 3(2021)
Authors: Q Lecocq, K Breckpot, Nick Devoogdt, M Keyaerts
Number of pages: 170 - Anti-human PD-L1 Nanobody for Immuno-PET Imaging(2020)
Authors: Jessica Bridoux, Katrijn Broos, Q Lecocq, P Debie, Charlotte Martin, Steven Ballet, G Raes, Sara Neyt, , K Breckpot, et al.
Pages: 1-15
Patents
1 - 2 of 2
- Anti lag3 vhhs and their use (Inventor)
- Anti lag3 vhhs and their use (Inventor)